times more common, and in African Americans, it is six steroid-resistant focal segmental glomerulosclerosis (FSGS) times more common than the second leading cause [1, 2].
was conducted. Despite the fact that it is the most common Although its pathology, natural history, and response to primary glomerulonephritis to progress to renal failure, treatment trials have been very limited.
corticosteroids treatment in both children and adults
Methods. We conducted a randomized controlled trial in 49 have been more clearly defined since its initial descripcases of steroid-resistant FSGS comparing 26 weeks of cyclospotion over 40 years ago [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , the number of randomized rine treatment plus low-dose prednisone to placebo plus predcontrolled drug trials in this disorder has been very limnisone. All patients were followed for an average of 200 weeks, ited [17] [18] [19] , and such a study in adults with pathology and the short-and long-term effects on renal function were restricted to FSGS has never been reported.
assessed.
Results. Seventy percent of the treatment group versus 4%
Cyclosporine is a well known and effective immunoof the placebo group (P Ͻ 0.001) had a partial or complete suppressive agent that has become a cornerstone of imremission of their proteinuria by 26 weeks. Relapse occurred munotherapy in solid organ transplantation since the in 40% of the remitters by 52 weeks and 60% by week 78, but first trial was published over a decade ago [20] . This drug the remainder stayed in remission to the end of the observation has been used in the treatment for FSGS for over 10 period. Renal function was better preserved in the cyclosporine group. There was a decrease of 50% in baseline creatinine years, but the studies have been open label and nonranclearance in 25% of the treated group compared with 52% of domized or have been a mixture of pathology and/or controls (P Ͻ 0.05). This was a reduction in risk of 70% (95% age groups [17] [18] [19] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Although a benefit in both CI, 9 to 93) independent of other baseline demographic and children and adults has been reported, enthusiasm for laboratory variables.
its use has been tempered by both a high relapse rate
Conclusions. These results suggest that cyclosporine is an and a concern about the known nephrotoxicity of the effective therapeutic agent in the treatment of steroid-resistant cases of FSGS. Although a high relapse rate does occur, a longagent [30, 32, 33] . We report the first long-term prospecterm decrease in proteinuria and preservation of filtration functive controlled trial using cyclosporine in adults with tion were observed in a significant proportion of treated patients.
biopsy-proven FSGS resistant to corticosteroid therapy.
METHODS

Focal segmental glomerulosclerosis (FSGS) is now the
This prospective single-blind, randomized trial was most common primary glomerulonephritis in the United performed in 12 clinical centers in North America. The study protocol was reviewed and approved by each cen-after a minimum of eight weeks of prednisone at Ն1 mg/ four-week intervals to zero by eight weeks. A seated blood pressure of Յ130 mm Hg systolic and Յ85 mm Hg kg/day. The following qualifiers had to be fulfilled for the full six months prior to randomization: (a) proteindiastolic was targeted as the upper limit of accepted values during the study. Any patient who was on either uria Ն3.5 g/day or Ն50 mg/kg, (b) creatinine clearance (C Cr ) Ն42 ml/min/1.73 m 2 , (c) blood pressure Յ135/90 an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor antagonist from the start of mm Hg, and (d) dietary protein intake Յ0.8 g/kg. All patients were required to have a renal biopsy performed the pretrial six-month run-in period could remain on it during the study, but the introduction of these classes within three years of trial entry, and the local pathology review had to confirm the presence of at least one classic of drug was forbidden during the test medication period. All other antihypertensive agents were allowed. Patients FSGS lesion [3] . Patients with features of collapsing glomerulopathy were excluded. The renal tissue was subwere placed on a diet consisting of Յ0.8 g/kg of protein plus, in most cases, a no added salt, low cholesterol intake sequently reviewed by a nephropathologist masked to patient assignment who scored each biopsy 0 to 3ϩ at the start of the observation period. Each patient had a minimum of three protocol visits (none, mild, moderate, or severe) with regards to three areas: the percentage of glomeruli with either segmental prior to randomization with two mandated within the six-week period prior to the start of the test medication. or global sclerosis, interstitial fibrosis, and vascular damage. Immunofluorescence and electron microscopy were At randomization, a full history and physical evaluation, as well as laboratory tests, including serum creatinine, also reviewed to rule out other types of renal disease known to be associated with segmental sclerotic lesions.
24-hour urinary excretion estimates of protein, creatinine and urea, a lipid profile including cholesterol and Exclusion criteria included women unwilling to take effective birth control measures, comorbid conditions triglyceride estimations, and screening tests to rule out potential secondary causes of FSGS, were performed. with expected survival of less than two years, any serious systemic infection and associated disorders requiring An inclusion/exclusion checklist was maintained centrally and reviewed prior to group assignment. The renal daily nonsteroidal anti-inflammatory medications. Patients with diabetes mellitus and conditions known to function tests were repeated on the day of randomization, and follow-up visits were scheduled for one, two, be associated with FSGS lesions such as obesity and unilateral renal agenesis were also excluded. No immufour, six, and eight weeks and then at four-week intervals until the end of the test medication period, and then at nosuppressive agents, plasma exchange therapy, or antilymphocyte products were allowed in the six months eight-week intervals until a study end point was reached or data closure (January 1, 1998). If specific immunosupprior to the start of the test medication period.
pressive drugs or corticosteroids were started at any time Randomization and treatment after the test medication period, the patients were censored at that point. At each visit, the patient's clinical Randomization was performed by the clinical coordinating center from a table of random numbers and was status and vital signs were recorded, and electrolytes, hematology, renal, and liver functions were monitored. stratified by center in blocks of two to ensure a balance between groups. The patients were masked in regards As well, cyclosporine trough values were obtained at these intervals during the first 26 weeks. Compliance was to active versus placebo assignment, but the physicians were not for safety reasons and because the end points determined by the consistency of the cyclosporine level and by a monthly check of the total volume consumed were objective and measured centrally by a lab masked to patient designation. Cyclosporine in a drink solution of the test medication. Serum creatinine and 24-hour urinary excretion of creatinine, protein, and urea at each (100 mg/ml) and an identical placebo made from the same carrier were provided by Novartis Canada Ltd. (Whitby, visit were measured by a central laboratory using standard methods. Ontario, Canada). Treatment was started at a dose of 3.5 mg/kg/day in the active group and 0.035 ml/kg in the Outcome measures placebo group. The daily quantity was divided and given in two equal doses at 12-hour intervals. Adjustments in
The primary outcome was the number of complete or partial remissions in proteinuria by week 26. This was dose were made in the cyclosporine group to achieve a whole blood 12-hour trough level measured by monoalso assessed at 52, 78, and 104 weeks, and at the last follow-up. Complete remission was defined as Յ0.3 g/day clonal assay, between 125 and 225 g/liter. A comparable number of adjustments were made in the placebo volume proteinuria plus stable renal function. A partial remission was defined as a 50% reduction of initial proteinuria to ensure that masking was maintained. The test medications were continued for 26 weeks and then tapered to and Յ3.5 g/day with stable renal function. Stable function was defined as a C Cr estimate that was within 15% of zero over four weeks. All study patients also received prednisone at 0.15 mg/kg/day (maximum daily dose of the initial value. Secondary analyses included time to a 50% reduction in baseline C Cr and time to doubling of 15 mg). This was reduced after 26 weeks by thirds at benefit of treatment was also assessed by calculating the number of patients who would need to be treated to prevent one outcome event defined by a 50% reduction in baseline C Cr [35] . baseline creatinine. Study end points included end-stage renal disease defined as a C Cr Ͻ12 ml/min, start of dial-RESULTS ysis, or transplantation or study closure. Early stop points of the test medication included a confirmed Ն30% rise Sixty patients were screened and deemed eligible by in baseline serum creatinine. Confirmed meant that the the local principal investigator, and signed a consent creatinine was not improved by two 25% reductions in form. Review subsequently excluded 11 patients prior the dose of the test medication, spaced out over a fourto randomization because of a failure to confirm the week period. Other premature stop points included douhistological diagnosis (N ϭ 4), central measurement of bling of baseline liver enzymes and intolerable side efproteinuria Ͻ 3.5 g/day (N ϭ 2), C Cr Ͻ 42 ml/min (N ϭ 4), fects. As well, the test medication was discontinued early and a positive antinuclear factor (N ϭ 1). if complete remission of proteinuria was achieved and
The total prednisone dose given prior to the six-month persisted for a minimum of one month.
run-in period was not different in the two groups. In the placebo patients, the mean was 100 mg/kg (range 80 to Data analysis 140), and in the cyclosporine patients, it was 120 mg/kg A prospective construction of sample size based on (range 70 to 150). The mean duration of treatment was an analysis of two independent proportions using an ␣ also similar at 14 weeks in the placebo patients (range of 0.05 and a ␤ of 0.2 and a difference in remission rates 10 to 48) and 13 weeks in the cyclosporine patients (range in proteinuria at 26 weeks of 30% plus a drop out rate 10 to 60). In addition, 11 patients (5 placebo and 6 cycloof 10%, indicated that 25 patients per arm were needed. sporine) had received a course of a cytotoxic agent (9 The subsequent results were analyzed by chi square for cyclophosphamide and 2 azathioprine) in a dose range of proportions and, if appropriate, the nonparametric Mann-1 to 3 mg/kg for a mean of two months (range 1 to 16). Whitney rank sum test. The length of time to event There were no significant differences in any of the analysis utilized Kaplan-Meier product-limit life-table demographic or laboratory features at baseline (Table 1) . survival estimates compared by the log-rank test. All
The racial group was predominantly Caucasian, and the tests were two sided and analyzed on the basis of all male to female ratio was approximately 2:1. The urine patients maintained in their original assigned group. Prourea, a reflection of dietary protein intake, was equal in portional hazards regression was used to determine posboth groups at entry. The central pathology review of sible interactions between treatment groups and baseline the renal biopsy tissue is detailed in Table 2 . All patients covariates, including age, gender, proteinuria, albumin, were documented to have at least one focal segmental systolic and diastolic blood pressure, and grade of intersclerotic lesion. The percentage of glomeruli with segstitial fibrosis on biopsy, as well as to estimate the reducmental lesions was variable from patient to patient, but tion in the number of events within groups. Differences the mean was not different between groups. The overall in renal functions over time were compared by t-test of interstitial fibrosis score and degree of vascular damage the slopes of C Cr and reciprocal of creatinine over the and their ranges were also very similar in both populations.
The effects of the test medication on the proteinuria 26 weeks of the test medications and over the total obser- Remission of proteinuria occurred in 69% of the cyclosporine group (12% complete and 57% partial) compared with a 4% partial remission rate in the placebo group by the end of the 26 weeks of active treatment min/year in the two groups at the end of six months of (P Ͻ 0.001). The time to complete remission ranged active treatment was the same, but over the study period, from 1 to 25 weeks and to partial remission from 1 to the mean was Ϫ5.5 ml/min Ϯ 18 in the cyclosporine 15 weeks with a mean of seven weeks. Two of three group compared with Ϫ23 ml/min Ϯ 39 in the placebo (66%) in complete remission and 6 of 15 (40%) in partial group (P Ͻ 0.05). Fourteen patients reached end-stage remission in the cyclosporine group relapsed by week 52.
renal disease by study closure (10 placebo and 4 A further three relapses and one new partial remission cyclosporine). The renal survival rate was 72% in the occurred by week 78 in this group. One further partial cyclosporine group compared with 49% in the placebo remission occurred in the placebo group at week 65.
group at four years (P ϭ 0.1). Seven patients were folThe percentage in remission then remained essentially lowed less than 78 weeks because of the onset of endunchanged at week 78 and 104. There was no statistical stage renal disease in six and because of relocation outrelationship in those who relapsed versus those who reside of North America in one. The latter patient was in mained long-term remitters between either the nadir the cyclosporine group, and her proteinuria and creatior percentage reduction achieved from their baseline nine had remained unchanged during both the treatment proteinuria.
period and in follow-up to week 36. Renal failure by log-rank test using a 50% reduction
The mean dose of cyclosporine over the treatment in baseline C Cr as an end point was seen in 25% of period was 4.2 Ϯ 2.1 mg/kg. All patients completed six the cyclosporine-treated patients compared with 52% of months of the test medication, except one on cyclosporine, placebo patients by four years (P Ͻ 0.05; Fig. 2) . Partial who had a complete remission by week 8 and stopped or complete remission of proteinuria whether they subsethe drug at week 12 and one who stopped cyclosporine quently relapsed was also significantly correlated with after 12 weeks because of persistent nausea and vomlong-term preservation of renal function (P Ͻ 0.03). This
iting. An increase in baseline creatinine of 30% incurred was not absolute because four partial remission patients in six patients, two on placebo and four on cyclosporine. (treatment ϭ 3, placebo ϭ 1) went on to reach a C Cr end After a dose adjustment, none in the placebo group but point. The number of patients needed to treat to prevent all four in the cyclosporine group had an improvement one occurrence of this end point was five. The associated in their creatinine value and remained on the test medicareduction in risk of progression was 70% (95% CI, 9 to tion to week 26. Compliance, as judged by a monthly 93) unaltered by any of the initial covariates examined, measurement of the volume of the test medications used, including age, gender, systolic and diastolic blood preswas Ն90% in all patients. sure, severity of baseline proteinuria, and degree of tubular interstitial disease on biopsy. The slope of C Cr in ml/ At randomization, 26% (N ϭ 13) of patients were
DISCUSSION
Focal segmental glomerulosclerosis was initially described 40 years ago. It is currently the most common primary glomerular disease to progress, and its incidence rate is increasing [1, 2, 12]. Although never formally tested, corticosteroid treatment is associated with a complete remission rate of between 20 and 40% [5] [6] [7] [8] . This type of response has also been noted to be the best single guide to an excellent long-term prognosis. In contrast, patients who do not respond have a higher likelihood of progressing to renal failure. This was our rationale for the entry criteria of failure to respond to a minimum of eight weeks of daily prednisone. The actual mean prednisone dose and duration were significantly greater of prednisone were equal to or above the amount given to induce remission in our earlier studies [5, 36] . In spite of this selection bias, our results demonstrated a signifinormotensive (5 placebo and 8 cyclosporine), and 74% cant effect of treatment with a reduction in proteinuria (N ϭ 36) were hypertensive. In the latter group, 21 were in 69% of the cyclosporine group, either partial (57%) on ACEi (10 placebo and 11 cyclosporine), and 15 were or complete remission (12%), compared with a very low on other antihypertensive drugs (8 placebo and 7 cyclopartial remission (4%) in the placebo group. Although the relapse rate was substantial with approximately 60% sporine). No significant differences in supine, sitting, or relapsing within the first-year post-test medication, the mean arterial blood pressure were noted during either remainder stayed in remission until the last follow-up. the active medication period or during the postdrug peAs well, the remission group, even if they subsequently riod (Fig. 3) . During the post-test medication period, relapsed, generally had a better long-term preservation hypertension worsened in both groups, and additional of filtration function, although as discussed, there were antihypertensive drugs were required. By the time the exceptions. Overall, however, a loss of 50% of renal funcpatient reached either a stop point or the last observation tion as measured by the halving of baseline C Cr was seen point, 88% (23 patients) in the cyclosporine group and in only one quarter of our cyclosporine patients, but over 87% (20 patients) in the placebo group were on at least half of our placebo group. In our multivariate analysis, one antihypertensive agent. At that point, an ACEi was the risk reduction of progression in the cyclosporine employed either alone or in combination with other antigroup was 70% (95% CI, 9 to 93) compared with placebo. hypertensive agents in 65% of the cyclosporine group A report from the only randomized controlled trial in and 85% of the placebo group (P ϭ NS).
children with FSGS demonstrated a mean reduction in proteinuria of 70 Ϯ 20% compared with 11 Ϯ 29% in the Adverse effects placebo group after six months of treatment [18] . The Although the mean blood pressure in the cyclosporine quantitative reduction was from 152 mg/kg to 37 mg/kg patients was maintained at the same level as the placebo body wt in the treated versus no change in the placebo group during the treatment period, a new agent or an group. In the only other controlled trial that included both increase in their antihypertensive drug dosage was readults and children but a mixture of minimal change and quired in eight of the cyclosporine patients and only two FSGS pathology, the authors found a remission rate of of the placebo group. The other significant adverse effect 60% with cyclosporine compared with 15% with conservawas in one patient who had gastrointestinal symptoms tive treatment after 12 months [17] . They also found that on cyclosporine and had to stop the medication after 12 long-term remission was preserved in approximately half weeks of treatment. All 49 patients were maintained on of their responders assessed at 12 months post-treatment. their prescribed prednisone dose for 26 weeks without There was no follow-up with regards to renal function any adverse effect.
in the study in children [18] . In the adult trial, although Dietary compliance over the study period was good the postmedication period was limited in both numbers with only 16% of the patients (4 placebo and 3 cyclospoof patients and the observation time, the decline in C Cr , rine) consistently more than 20% above the recomalbeit not statistically significant, was slower, both during mended dietary protein intake, as assessed by monthly the treatment and in the 12 months of follow-up in the cyclosporine group [17]. 24-hour urinary urea estimates. by us and others [21, 37] and was the rationale for the suggesting that it was a reversible hemodynamic effect 4. Cameron JS, Turner DR, Ogg CS, Chantler C, Williams DG:
The long-term prognosis of patients with focal segmental glomeru- [38, 39] . In contrast, no improvement was seen in the two and/or retreatment of relapses were not part of this trial. 
